State of the evidence: Evidence level: small uncontrolled human studies focused on PSA measures. These findings do not establish cancer treatment efficacy or longer survival.
Why the study population matters
These studies do not represent every person with prostate cancer. Biochemical recurrence describes a renewed PSA rise after previous treatment. Eligibility criteria select people with particular treatment histories, imaging findings and PSA patterns. Findings from that group cannot automatically be transferred to newly diagnosed disease, widespread cancer or people receiving substantially different therapies. The population defines the question being asked.
What the early studies reported
The 2003 pilot assessed 13 men for tolerability and 10 for efficacy; seven evaluable participants had longer PSA doubling times. There was no control group.[1] The 2021 single-arm study enrolled 60 people, analyzed 59 and reported longer doubling times in 44 participants after six months.[2]
The 2021 paper disclosed manufacturer support and one author’s connection to the sponsoring company.[2] This does not automatically invalidate the findings, but reinforces the importance of independent replication.
The missing comparison
A single-arm study can describe what happened while participants took a supplement. It cannot directly reveal what would have happened without it under otherwise similar conditions. Comparing participants with their own earlier measurements is informative, but does not remove every explanation related to time, measurement or selection. An observed change and a demonstrated treatment effect therefore remain different conclusions.
A laboratory outcome is not a survival outcome
A slower change in a laboratory marker can justify further investigation. Establishing that an intervention extends life, prevents metastasis or reduces treatment requirements calls for evidence addressing those outcomes. When reading a paper, check the endpoint before accepting a broad interpretation of its conclusion. In particular, the word response must be read according to the study's own definition.
Bringing the evidence to a clinical discussion
A useful discussion starts with the paper, the exact product and a complete medication list, rather than a headline percentage. Your clinician can compare the participants with your disease stage, previous treatment and monitoring plan. This article provides questions for that conversation, rather than instructions to change treatment. Different preparations should not be assumed equivalent simply because their labels use the same ingredient name.
What a stronger next study would provide
Look for an appropriate comparison group, predefined outcomes, enough participants and consistent follow-up. Reports should also make it clear how participants who left the study were handled. This framework allows an early signal to remain interesting without enlarging its meaning. The most useful conclusion is proportionate: a research observation can support another study while still leaving its importance for patient care unresolved.
References
This article provides general health information. Research findings about MCP are not individual recommendations for diagnosing or treating disease. Medicine and supplement use should be discussed with a doctor or pharmacist.
Published and sources assessed: 17 October 2026